Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 2
2000 1
2004 2
2007 5
2009 2
2010 4
2011 2
2012 6
2013 7
2014 4
2015 2
2016 4
2017 3
2018 2
2019 3
2020 4
2021 6
2022 3
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Curtis JR, Karis E, Yen PK, Kricorian G, Chung JB. Curtis JR, et al. Among authors: kricorian g. Arthritis Rheumatol. 2021 Sep;73(9):1771-1772. doi: 10.1002/art.41718. Epub 2021 Aug 9. Arthritis Rheumatol. 2021. PMID: 33750019 No abstract available.
Reply.
Mease PJ, Collier DH, Kricorian G, Chung JB. Mease PJ, et al. Among authors: kricorian g. Arthritis Rheumatol. 2020 Jul;72(7):1229-1230. doi: 10.1002/art.41273. Epub 2020 May 28. Arthritis Rheumatol. 2020. PMID: 32266796 No abstract available.
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target.
Croft M, Esfandiari E, Chong C, Hsu H, Kabashima K, Kricorian G, Warren RB, Wollenberg A, Guttman-Yassky E. Croft M, et al. Among authors: kricorian g. Am J Clin Dermatol. 2024 Jan 18. doi: 10.1007/s40257-023-00838-9. Online ahead of print. Am J Clin Dermatol. 2024. PMID: 38236520 Review.
Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.
Nirula A, Nilsen J, Klekotka P, Kricorian G, Erondu N, Towne JE, Russell CB, Martin DA, Budelsky AL. Nirula A, et al. Among authors: kricorian g. Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii43-ii55. doi: 10.1093/rheumatology/kew346. Rheumatology (Oxford). 2016. PMID: 27856660 Review.
Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry.
Pappas DA, O'Brien J, Guo L, Shan Y, Baker JF, Kricorian G, Stryker S, Collier DH. Pappas DA, et al. Among authors: kricorian g. Arthritis Res Ther. 2023 Sep 9;25(1):166. doi: 10.1186/s13075-023-03120-9. Arthritis Res Ther. 2023. PMID: 37689684 Free PMC article.
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S. Papp KA, et al. Among authors: kricorian g. N Engl J Med. 2012 Mar 29;366(13):1181-9. doi: 10.1056/NEJMoa1109017. N Engl J Med. 2012. PMID: 22455412 Free article. Clinical Trial.
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis.
Coates LC, Merola JF, Mease PJ, Ogdie A, Gladman DD, Strand V, van Mens LJJ, Liu L, Yen PK, Collier DH, Kricorian G, Chung JB, Helliwell PS. Coates LC, et al. Among authors: kricorian g. Rheumatology (Oxford). 2021 Mar 2;60(3):1137-1147. doi: 10.1093/rheumatology/keaa271. Rheumatology (Oxford). 2021. PMID: 32864685 Free PMC article. Clinical Trial.
61 results